Design Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Design Therapeutics Current Ratio Growth & History (DSGN)
Design Therapeutics's current ratio was 17.14 for fiscal 2025.
View full Design Therapeutics company overviewDesign Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 17.14 | −12.17 | −41.52% |
| 2024 | 2024-12-31 | 29.31 | −0.26 | −0.89% |
| 2023 | 2023-12-31 | 29.58 | −1.52 | −4.89% |
| 2022 | 2022-12-31 | 31.10 | −41.86 | −57.37% |
| 2021 | 2021-12-31 | 72.96 | 57.41 | +369.16% |
| 2020 | 2020-12-31 | 15.55 | — | — |
Design Therapeutics quarterly current ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 18.86 | −6.27 | −24.93% |
| Q1 2026 | 2026-03-31 | 22.28 | −6.09 | −21.46% |
| Q4 2025 | 2025-12-31 | 17.14 | −12.17 | −41.52% |
| Q3 2025 | 2025-09-30 | 18.71 | −15.90 | −45.95% |
| Q2 2025 | 2025-06-30 | 25.13 | −16.29 | −39.33% |
| Q1 2025 | 2025-03-31 | 28.37 | −10.24 | −26.52% |
| Q4 2024 | 2024-12-31 | 29.31 | −0.26 | −0.89% |
| Q3 2024 | 2024-09-30 | 34.61 | 10.84 | +45.60% |
| Q2 2024 | 2024-06-30 | 41.42 | 16.20 | +64.21% |
| Q1 2024 | 2024-03-31 | 38.61 | 3.35 | +9.52% |
| Q4 2023 | 2023-12-31 | 29.58 | −1.52 | −4.89% |
| Q3 2023 | 2023-09-30 | 23.77 | −9.70 | −28.97% |
| Q2 2023 | 2023-06-30 | 25.22 | −23.74 | −48.48% |
| Q1 2023 | 2023-03-31 | 35.25 | −32.97 | −48.33% |
| Q4 2022 | 2022-12-31 | 31.10 | −41.86 | −57.37% |
| Q3 2022 | 2022-09-30 | 33.47 | −38.34 | −53.39% |
| Q2 2022 | 2022-06-30 | 48.96 | −69.95 | −58.82% |
| Q1 2022 | 2022-03-31 | 68.22 | −42.88 | −38.59% |
| Q4 2021 | 2021-12-31 | 72.96 | 57.41 | +369.16% |
| Q3 2021 | 2021-09-30 | 71.81 | — | — |
| Q2 2021 | 2021-06-30 | 118.91 | — | — |
| Q1 2021 | 2021-03-31 | 111.10 | — | — |
| Q4 2020 | 2020-12-31 | 15.55 | — | — |
Design Therapeutics current ratio trends
Over the last five fiscal years, Design Therapeutics's current ratio increased from 15.55 to 17.14, a change of 1.59. The latest reported quarter, Q2 2026, shows 18.86.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Design Therapeutics source filings ↗